H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $25 from $36 and keeps a Buy rating on the shares following the Q2 report. The firm reduced estimates for the Ojemda launch.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN: